CA2007463A1 - Distributeurs commandes par hydrogel - Google Patents

Distributeurs commandes par hydrogel

Info

Publication number
CA2007463A1
CA2007463A1 CA2007463A CA2007463A CA2007463A1 CA 2007463 A1 CA2007463 A1 CA 2007463A1 CA 2007463 A CA2007463 A CA 2007463A CA 2007463 A CA2007463 A CA 2007463A CA 2007463 A1 CA2007463 A1 CA 2007463A1
Authority
CA
Canada
Prior art keywords
hydrogel
powered
beneficial agents
devices
dispensing devices
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2007463A
Other languages
English (en)
Other versions
CA2007463C (fr
Inventor
William John Curatolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2007463A1 publication Critical patent/CA2007463A1/fr
Application granted granted Critical
Publication of CA2007463C publication Critical patent/CA2007463C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • External Artificial Organs (AREA)
  • Prostheses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002007463A 1989-01-12 1990-01-10 Distributeurs commandes par hydrogel Expired - Fee Related CA2007463C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29646489A 1989-01-12 1989-01-12
US296,464 1989-01-12

Publications (2)

Publication Number Publication Date
CA2007463A1 true CA2007463A1 (fr) 1990-07-12
CA2007463C CA2007463C (fr) 1995-01-17

Family

ID=23142114

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002007463A Expired - Fee Related CA2007463C (fr) 1989-01-12 1990-01-10 Distributeurs commandes par hydrogel

Country Status (19)

Country Link
US (2) US5516527A (fr)
EP (1) EP0378404B1 (fr)
JP (1) JPH07119171B2 (fr)
KR (1) KR920008702B1 (fr)
AT (1) ATE110578T1 (fr)
AU (1) AU615129B2 (fr)
CA (1) CA2007463C (fr)
DE (1) DE69011878T2 (fr)
DK (1) DK0378404T3 (fr)
ES (1) ES2058775T3 (fr)
FI (1) FI900153A (fr)
HU (1) HUT54038A (fr)
IE (1) IE64201B1 (fr)
IL (1) IL92966A (fr)
MY (1) MY105761A (fr)
NO (1) NO900151L (fr)
NZ (1) NZ232078A (fr)
PT (1) PT92838B (fr)
ZA (1) ZA90197B (fr)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
CA2115648C (fr) * 1991-10-10 2002-04-09 Eun Soo Lee Elements a parois hydrophobes pour l'administration de medicaments par osmose
PL171110B1 (pl) * 1991-12-27 1997-03-28 Merck & Co Inc Sposób wytwarzania tabletki do kontrolowanego wytwarzania i uwalniania in situ dyspersji zawierajacej lek PL PL PL
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
ZA935569B (en) * 1992-07-31 1994-04-12 Daratech Pty Ltd Controlled release implants
RO112991B1 (ro) * 1992-09-18 1998-03-30 Yamanouchi Pharma Co Ltd Preparat tip hidrogel, cu eliberare sustinuta
JPH06256166A (ja) * 1993-01-06 1994-09-13 ▲寛▼治 ▲高▼田 薬物放出制御製剤
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
WO1998018452A1 (fr) * 1996-10-25 1998-05-07 Shire Laboratories, Inc. Systeme osmotique d'administration de doses sous forme soluble
EP1027888B1 (fr) * 1999-02-10 2009-06-10 Pfizer Products Inc. Dispositif osmotique pour délivrer des dispersions solides amorphes des médicaments
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6228392B1 (en) * 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
US6251432B1 (en) * 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
WO2001047498A2 (fr) 1999-12-23 2001-07-05 Pfizer Products Inc. Forme de dosage d'un medicament stratifie entraine par un hydrogel
MXPA02006328A (es) * 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmacos accionada por un hidrogel.
EA006402B1 (ru) 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
US6296993B1 (en) 2000-06-13 2001-10-02 Eastman Kodak Company Method of providing digitized photographic image
US6309810B1 (en) 2000-06-13 2001-10-30 Eastman Kodak Company Photochemical delivery article and method of use
US6361225B1 (en) 2000-06-13 2002-03-26 Eastman Kodak Company Apparatus for providing a photochemical reaction
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US6770721B1 (en) * 2000-11-02 2004-08-03 Surface Logix, Inc. Polymer gel contact masks and methods and molds for making same
JPWO2002064114A1 (ja) * 2001-02-15 2004-06-10 株式会社三和化学研究所 新規眼科用組成物
CA2441064A1 (fr) * 2001-03-16 2002-09-26 Andrx Corporation Preparation de sulfonyluree a liberation controlee
US20030008007A1 (en) * 2001-04-23 2003-01-09 Jose Gutierrez-Rocca Release pharmaceutical construct for gastric retention
BR0212950A (pt) * 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas tendo uma porção inserida
JP2005528330A (ja) * 2001-11-30 2005-09-22 ファイザー・プロダクツ・インク ５，７，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１）３，５，７，９−ペンタエンの医薬組成物
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
EP1503740A1 (fr) * 2002-05-06 2005-02-09 Ranbaxy Laboratories Limited Systeme monocompartiment d'administration de medicament a regulation osmotique
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2003256844A1 (en) * 2002-07-29 2004-02-16 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
UY28326A1 (es) * 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
JP5628467B2 (ja) * 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
SI1635875T1 (sl) 2003-06-26 2009-04-30 Psivida Inc Sistem za dajanje zdravila, ki se gelira in situ
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
AU2005268003B2 (en) * 2004-08-02 2009-06-11 Samyang Biopharmaceuticals Corporation Biodegradable multi-block polymeric composition capable of sol-gel transition
EP1824491A1 (fr) * 2004-11-22 2007-08-29 Ranbaxy Laboratories Limited Systeme de liberation monocompartimental de doxazosine a regulation osmotique
JP2007070344A (ja) * 2005-08-11 2007-03-22 Tsukioka:Kk 内服薬
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP2664337B1 (fr) 2005-09-27 2019-08-14 TissueTech, Inc. Preparations de membrane amniotique et compositions purifiees, et procedes d'utilisation
NZ543314A (en) * 2005-10-28 2007-08-31 Interag A delivery system where the driving substance contains the active component
KR101405545B1 (ko) 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
US20080090897A1 (en) 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
CA2695526A1 (fr) * 2006-08-11 2008-02-21 Feg Holdings, Llc Dispositif exercant une pression hemostatique et presentant une haute vitesse de gonflement
PL2529621T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
US8812637B2 (en) * 2006-11-28 2014-08-19 International Business Machines Corporation Aggregation of multiple media streams to a user
US20080127272A1 (en) * 2006-11-28 2008-05-29 Brian John Cragun Aggregation of Multiple Media Streams to a User
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
AU2008299220B2 (en) 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2715584A1 (fr) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd. Comprime oral a liberation controlee
US7981925B2 (en) 2008-08-27 2011-07-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2421901B1 (fr) 2009-04-24 2015-10-28 Tissue Tech, Inc. Composition contenant le complexe hc ha et procédés d'utilisation de celle-ci
LT2442791T (lt) 2009-06-16 2020-02-25 Pfizer Inc. Apiksabano vaisto formos
WO2011006066A1 (fr) 2009-07-10 2011-01-13 Ironwood Pharmaceuticals, Inc. Agonistes des récepteurs cb
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
NZ599524A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Polysaccharide based hydrogels
US8795727B2 (en) 2009-11-09 2014-08-05 Spotlight Technology Partners Llc Fragmented hydrogels
AU2010333829A1 (en) 2009-12-23 2012-07-12 Ironwood Pharmaceuticals, Inc. CRTH2 modulators
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
WO2011115804A1 (fr) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
WO2011118454A1 (fr) * 2010-03-23 2011-09-29 リンテック株式会社 Préparation solide
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
AU2011248579A1 (en) 2010-04-27 2012-11-29 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011139489A2 (fr) 2010-04-27 2011-11-10 Calcimedica Inc. Composés capables de moduler le calcium intracellulaire
AU2011261185A1 (en) 2010-06-03 2013-01-10 Pharmacyclics, Inc. The use of inhibitors of Bruton's tyrosine kinase (Btk)
US8748442B2 (en) 2010-06-30 2014-06-10 Ironwood Pharmaceuticals, Inc. sGC stimulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (fr) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Modulateurs de crth2
MX337711B (es) 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
AU2011326241B2 (en) 2010-11-09 2016-11-17 Ironwood Pharmaceuticals, Inc. sGC stimulators
WO2012149486A1 (fr) 2011-04-28 2012-11-01 Tissuetech, Inc. Procédés de modulation de remodélisation osseuse
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
EP3112363A1 (fr) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. Dérivés de pyrimidine 2-[1-[(2-fluorophényl)méthyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl] et composés similaires en tant que stimulateurs de la cyclase soluble du guanylate (csg) pour le traitement de l'hypertension pulmonaire
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
LT2800565T (lt) 2012-01-06 2020-07-27 Lundbeck La Jolla Research Center, Inc. Karbamato junginiai ir jų gamybos būdai ir panaudojimai
US9046085B2 (en) * 2012-03-14 2015-06-02 Eden Medical, Inc. Miniature pumps
WO2013155422A1 (fr) 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Procédés permettant de traiter l'alopécie et l'acné
CA3218491A1 (fr) 2012-06-04 2013-12-12 Pharmacyclics Llc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
JP2015528001A (ja) 2012-07-11 2015-09-24 ティッシュテック，インク． Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
AU2013323206B2 (en) 2012-09-28 2017-07-20 Fred Hutchinson Cancer Center Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
WO2014059333A1 (fr) 2012-10-12 2014-04-17 Calcimedica, Inc. Composés qui modulent le calcium intracellulaire
US10172791B2 (en) * 2013-03-14 2019-01-08 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
US9555007B2 (en) 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
IL285564B2 (en) 2013-03-15 2024-06-01 Cyclerion Therapeutics Inc sGC fans
WO2015054283A1 (fr) 2013-10-08 2015-04-16 Calcimedica, Inc. Composés qui modulent le calcium intracellulaire
GB201319791D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
EP3092231B1 (fr) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Stimulateurs de la sgc
CN104971414A (zh) * 2014-04-01 2015-10-14 黄震山 药物缓释器
EP3134418A4 (fr) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York Réaction de ligature bio-orthogonale rapide et efficace et hétérocycles contenant du bore utiles en association avec celle-ci
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
MX2017003518A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA2974395C (fr) 2015-02-06 2023-08-22 University Of Washington Composes et procedes pour prevenir ou traiter la mort de cellules capillaires sensorielles
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
TW201642914A (zh) 2015-02-23 2016-12-16 組織科技股份有限公司 用於治療眼部疾病及失調的裝置及方法
SG11201706989SA (en) 2015-02-27 2017-09-28 Curtana Pharmaceuticals Inc Inhibition of olig2 activity
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
EP3297645A4 (fr) 2015-05-20 2018-12-12 Tissuetech, Inc. Compositions et procédés pour la prévention de la prolifération et de la transition épithélio-mésenchymateuse des cellules épithéliales
EP3344254A1 (fr) 2015-08-31 2018-07-11 Pharmacyclics LLC Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
DK3827838T5 (en) 2015-12-16 2024-08-19 Walter & Eliza Hall Inst Medical Res Hæmning af cytokin-induceret sh2-protein i nk-celler
US20190290650A1 (en) 2016-01-19 2019-09-26 Janssen Pharmaceutic Nv Formulations/compositions comprising a btk inhibitor
BR112018014590A2 (pt) 2016-01-19 2018-12-11 Janssen Pharmaceutica Nv formulações/composições compreendendo um inibidor de btk
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3442538A4 (fr) 2016-04-04 2019-11-20 Sinopia Biosciences, Inc. Traitement de syndrome extrapyramidal à l'aide de trapidil
CN109562281B (zh) 2016-05-25 2021-12-17 同心镇痛药物公司 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
WO2017205766A1 (fr) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibiteurs de la kinase associée au récepteur de l'interleukine-1
WO2017205769A1 (fr) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibiteurs de la kinase associée au récepteur de l'interleukine 1
WO2017205762A1 (fr) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibiteurs de la kinase associée au récepteur de l'interleukine 1
PL3484862T3 (pl) 2016-07-18 2022-01-31 Arthrosi Therapeutics, Inc. Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią
EA201990508A1 (ru) 2016-08-26 2019-09-30 Куртана Фармасьютикалс, Инк. ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
MX2019002313A (es) 2016-09-02 2019-07-08 Cyclerion Therapeutics Inc Estimuladores de guanilato ciclasa soluble (sgc) biciclicos fusionados.
EP3538096B1 (fr) 2016-11-08 2024-02-28 Tisento Therapeutics Inc. Traitement de maladies du snc au moyen de stimulateurs de gcs
US11180493B2 (en) 2016-11-08 2021-11-23 Cyclerion Therapeutics, Inc. SGC stimulators
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
CN115093382A (zh) 2016-11-16 2022-09-23 H.隆德贝克有限公司 Magl抑制剂的结晶形式
KR20200086257A (ko) 2017-09-01 2020-07-16 유니버시티 오브 워싱톤 감각 모 세포 사멸 예방 또는 치료용 화합물의 결정질 형태
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
CA3107433A1 (fr) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Promedicaments pegyles d'agonistes du trpv1 phenolique
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
KR20220009373A (ko) 2019-03-15 2022-01-24 유니사이시브 테라퓨틱스 인코포레이티드 니코란딜 유도체
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2022150525A1 (fr) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma dans le traitement d'un trouble de consommation d'alcool
US20240190809A1 (en) 2021-05-11 2024-06-13 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
AU2022283967A1 (en) 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
MX2024002189A (es) 2021-08-20 2024-06-11 Biomea Fusion Inc Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
WO2023028091A1 (fr) 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Empathogènes deutérés
WO2023027966A1 (fr) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3
WO2023039240A1 (fr) 2021-09-13 2023-03-16 Biomea Fusion, Inc. Inhibitors irréversibles de kras
WO2023086341A1 (fr) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibiteurs de kras
KR20240128987A (ko) 2021-12-30 2024-08-27 바이오메아 퓨전, 인크. Flt3의 억제제로서의 피라진 화합물
WO2023139163A1 (fr) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited Esters de 1,3-benzodioxole et leur utilisation thérapeutique
WO2023156565A1 (fr) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Composes cycliques pontés et leur utilisation thérapeutique comme agents du snc
WO2023235618A1 (fr) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Composés de pyrimidine fusionnés en tant qu'inhibiteurs de la ménine
US20240010649A1 (en) 2022-07-06 2024-01-11 Oppilan Pharma Limited Crystalline forms of an s1p receptor modulator
WO2024155719A1 (fr) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phényl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-pipéridinyl]méthyl]-2- pyridinecarboxamide en tant qu'inhibiteur covalent de l'interaction ménine-mll

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4180073A (en) * 1977-08-29 1979-12-25 Alza Corporation Device for delivering drug to biological environment
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4320759A (en) * 1980-04-28 1982-03-23 Alza Corporation Dispenser with diffuser
US4350271A (en) * 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4663286A (en) * 1984-02-13 1987-05-05 Damon Biotech, Inc. Encapsulation of materials
US4772474A (en) * 1985-08-09 1988-09-20 Alza Corporation Dispenser with internal arrangement of lamina means for dispensing beneficial agent
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4595583A (en) * 1984-03-19 1986-06-17 Alza Corporation Delivery system controlled administration of beneficial agent to ruminants
US4678467A (en) * 1984-03-21 1987-07-07 Alza Corporation Dispenser comprising capsule with volume displacing member
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
CA1266827A (fr) * 1984-06-20 1990-03-20 Merck & Co., Inc. Pompe osmotique a porosite controlee
US4608048A (en) * 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
CA1242394A (fr) * 1985-03-07 1988-09-27 Neil B. Graham Dispositif a liberation controlee
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4716496A (en) * 1986-05-09 1987-12-29 Eaton Corporation Panel-mounted control station housing
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
DE3769707D1 (de) * 1986-06-17 1991-06-06 Recordati Chem Pharm Therapeutisches system mit geregelter wirkstoffabgabe.
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DE3629994A1 (de) * 1986-09-03 1988-03-17 Weissenbacher Ernst Rainer Pro Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices

Also Published As

Publication number Publication date
NO900151D0 (no) 1990-01-11
FI900153A0 (fi) 1990-01-11
US5516527A (en) 1996-05-14
PT92838B (pt) 1996-02-29
EP0378404A3 (en) 1990-10-03
IE64201B1 (en) 1995-07-12
ES2058775T3 (es) 1994-11-01
NO900151L (no) 1990-07-13
HU900108D0 (en) 1990-03-28
US5792471A (en) 1998-08-11
AU615129B2 (en) 1991-09-19
KR920008702B1 (ko) 1992-10-08
HUT54038A (en) 1991-01-28
AU4787790A (en) 1990-07-19
ZA90197B (en) 1991-07-31
ATE110578T1 (de) 1994-09-15
IL92966A (en) 1995-07-31
IE900104L (en) 1990-07-12
EP0378404B1 (fr) 1994-08-31
DK0378404T3 (da) 1994-10-03
FI900153A (fi) 1990-07-13
JPH07119171B2 (ja) 1995-12-20
DE69011878T2 (de) 1994-12-15
EP0378404A2 (fr) 1990-07-18
NZ232078A (en) 1991-02-26
JPH02229110A (ja) 1990-09-11
MY105761A (en) 1995-01-30
IL92966A0 (en) 1990-09-17
PT92838A (pt) 1990-07-31
DE69011878D1 (de) 1994-10-06
KR900011486A (ko) 1990-08-01
CA2007463C (fr) 1995-01-17

Similar Documents

Publication Publication Date Title
AU615129B2 (en) Dispensing devices powered by hydrogel
AU652135B2 (en) Two-part device for the controlled delivery of an active ingredient
AU6973591A (en) Transdermal system
AU5106890A (en) Device for the transdermal delivery of nicotine
AU2152688A (en) Dosage form comprising fast agent delivery followed by slow agent delivery
AU3119195A (en) Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
AU3619295A (en) Antiinflammatory agent for external use
EP1138345A3 (fr) Une matrice pour l' iontophorèse
AU4787690A (en) Dispensing devices powered by lyotropic liquid crystals
EP0347864A3 (fr) Agents antiathérogéniques
CA2163118A1 (fr) Fractions d'acide aurintricarboxylique et analogues avec activite anti-angiogenique; methodes d'utilisation
CA2118030A1 (fr) Medicament servant a elever la concentration de testosterone dans l'organisme
AU6624896A (en) Pharmaceutical composition
AU7313896A (en) Pharmaceutical composition containing an activin or inhibin stimulator
AU2399188A (en) Device for the pulsed delivery of an irrigation liquid, and irrigation facilities incorporating the same device
AU5374090A (en) Controlled delivery devices
CA2002472A1 (fr) Formule orale liquide
AU1174588A (en) Anticonvulsant agents
AU3168089A (en) Azaneophyl and silazaneophyl sulfides, processes for their preparation, agents containing them, and their use as pesticides
AU664101B2 (en) Novel phospholipid derivatives
IT230454Y1 (it) Dispositivo di comando dell'accelleratore per autovetture destinate ad utenti privi dell'uso degli arti inferiori
AU4419589A (en) Device for allowing the emanation of aromas or essential oils
AU7719491A (en) Therapeutic compound
ZA9010280B (en) Two-part device for the controlled delivery of an active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed